Prometrium Cost in New York (2026): Cash Prices, Insurance, Medicaid, and Savings

What Prometrium Actually Costs in New York Right Now

The average cash-pay price for a 30-day supply of Prometrium 200 mg in New York sits at roughly $45 per month in 2026, well below the AbbVie list price of approximately $180. Generic micronized progesterone capsules, bioequivalent to Prometrium per FDA standards, account for most of this price drop since their entry into the market following the Hatch-Waxman abbreviated approval pathway.

Prices vary meaningfully across New York boroughs and regions. Manhattan pharmacies tend to charge $50 to $65 for cash-pay fills, while pharmacies in Buffalo, Rochester, and upstate counties often price below $40. Chain pharmacies like CVS, Walgreens, and Rite Aid all stock generic micronized progesterone statewide. The FDA-approved labeling for Prometrium specifies 200 mg once daily at bedtime for 12 sequential days per 28-day cycle when used for endometrial protection alongside conjugated estrogens, though many clinicians now prescribe continuous nightly dosing for women on daily transdermal estradiol [1]. The PEPI trial (N=875) established that micronized progesterone 200 mg for 12 days per cycle prevented endometrial hyperplasia as effectively as medroxyprogesterone acetate while producing a more favorable lipid profile [2].

New York Medicaid Coverage for Prometrium

New York Medicaid covers Prometrium and its generic equivalents, but requires prior authorization. The prescribing clinician must document that the patient needs progesterone for endometrial protection on hormone replacement therapy or for another FDA-approved indication. PA turnaround in New York typically takes 24 to 72 hours through the state's Medicaid managed care organizations.

The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy recommends micronized progesterone over synthetic progestins when feasible, citing a lower breast cancer signal in observational data [3]. New York Medicaid formulary committees have recognized this preference, which strengthens PA approval rates. The E3N French cohort study (N=80,377) showed no significant increase in breast cancer risk with micronized progesterone combined with transdermal estradiol over a mean follow-up of 8.1 years, compared with the elevated risk seen with synthetic progestins [4]. This finding supports the clinical rationale that Medicaid reviewers accept during the PA process.

For women enrolled in Medicaid managed care plans like Fidelis, Healthfirst, or Amerigroup in New York, the co-pay is typically $0 to $3 for preferred generics. If the PA is denied, physicians can file a fair hearing appeal through the New York State Department of Health within 60 days.

Insurance Coverage Beyond Medicaid

Most commercial insurance plans in New York cover generic micronized progesterone on a preferred tier. Tier placement matters. A Tier 1 generic co-pay in the New York market usually runs $5 to $15 per fill, while brand-name Prometrium on Tier 2 or Tier 3 can cost $35 to $75 in co-pay.

Employer-sponsored plans through major carriers like UnitedHealthcare, Aetna, and Empire Blue Cross Blue Shield all include generic micronized progesterone on their standard formularies without step therapy requirements [5]. The Women's Health Initiative estrogen-plus-progestin trial used medroxyprogesterone acetate, not micronized progesterone, making it important to distinguish the two when reviewing coverage rationale [6]. Some plans may initially default-cover medroxyprogesterone and require a formulary exception for micronized progesterone. In such cases, citing the 2017 North American Menopause Society position statement on hormone therapy, which acknowledges the potential advantages of micronized progesterone, can support the exception request [7].

New York's Essential Plan, available to residents earning 138% to 200% of the federal poverty level, also covers progesterone products. Co-pays under the Essential Plan are capped at $1 for generic drugs.

Compounded Micronized Progesterone in New York: Legality and Cost

Compounded micronized progesterone is legal in New York through licensed 503A pharmacies operating under the oversight of the New York State Board of Pharmacy. The cost typically runs about $25 per month for a 30-day supply of 200 mg capsules.

A key distinction: 503A pharmacies compound on a patient-specific basis with an individual prescription, while 503B outsourcing facilities registered with the FDA produce larger batches under current good manufacturing practice requirements [8]. New York permits both types. The state board conducts regular inspections and requires compounding pharmacies to comply with USP Chapter 795 standards for nonsterile preparations [9].

Compounded progesterone may use a different suspension base than the peanut oil used in brand Prometrium, which matters for patients with peanut allergies. The American College of Obstetricians and Gynecologists Committee Opinion 789 acknowledges that compounded bioidentical hormones contain the same molecular structures as FDA-approved products but cautions that compounded formulations lack the standardized testing, labeling, and pharmacokinetic validation required for FDA-approved drugs [10]. Women considering compounded micronized progesterone should discuss bioequivalence considerations with their prescriber.

New York City has a high density of compounding pharmacies, with over 40 licensed 503A facilities in Manhattan and Brooklyn alone. Upstate options include compounding pharmacies in Albany, Syracuse, and the Hudson Valley.

Telehealth Prescribing of Prometrium in New York

New York fully permits telehealth prescribing of Prometrium and generic micronized progesterone. The state made its pandemic-era telehealth expansions permanent through legislation in 2023, allowing prescribers to initiate hormone therapy via video or audio-only visits.

For menopausal hormone therapy, the 2022 Hormone Therapy Position Statement of The North American Menopause Society supports individualized prescribing based on symptom burden, cardiovascular risk, and personal history [11]. Telehealth platforms operating in New York can prescribe, manage dosing adjustments, and order follow-up labs for progesterone therapy remotely. The New York State Education Department requires that telehealth prescribers hold an active New York license and maintain a patient relationship that meets the same standard of care as in-person visits.

HealthRX provides telehealth hormone therapy consultations for New York residents, including progesterone prescribing with home delivery. Patients do not need a prior in-person visit to begin treatment.

How to Lower Your Prometrium Cost in New York

Several concrete strategies reduce out-of-pocket cost. The single most effective step is filling the generic rather than the brand. That alone saves $100 or more per month in most New York pharmacies.

The AbbVie savings card, originally launched under Solvay Pharmaceuticals and continued by AbbVie after acquisition, offers eligible commercially insured patients reduced co-pays on brand Prometrium. Patients with government insurance (Medicaid, Medicare, Tricare) do not qualify for the manufacturer card. The FDA Orange Book lists generic micronized progesterone capsules with an "AB" therapeutic equivalence rating to Prometrium, confirming substitutability at the pharmacy counter [12].

Additional cost-reduction approaches for New York residents:

• GoodRx and RxSaver coupons: These pharmacy discount aggregators frequently list generic micronized progesterone at $20 to $35 for a 30-day supply at New York pharmacies.
• Mark Cuban Cost Plus Drugs: Offers generic micronized progesterone at a transparent markup over manufacturer cost, typically priced under $15 for a 30-day supply with mail delivery to New York.
• 90-day fills: Many insurers and mail-order pharmacies offer a 90-day supply for two co-pays instead of three, reducing per-month cost by roughly 33%.
• New York Prescription Saver Discount Card: The state-sponsored program, available at ny.gov, provides discounts at participating pharmacies statewide for uninsured and underinsured residents.

Clinical Context: Why Micronized Progesterone Over Synthetic Progestins

The cost conversation matters more when you understand why clinicians increasingly prefer micronized progesterone. The PEPI trial demonstrated equivalent endometrial protection but showed micronized progesterone preserved the HDL cholesterol benefit of estrogen therapy, while medroxyprogesterone acetate blunted the HDL increase by approximately 50% [2].

More recently, the REPLENISH trial (N=1,845) evaluated a combined estradiol/progesterone capsule (TX-001HR, marketed as Bijuva) and confirmed the efficacy and safety profile of micronized progesterone for endometrial protection in a modern regulatory trial [13]. The study found no cases of endometrial hyperplasia over 12 months at the 1 mg estradiol / 100 mg progesterone dose.

The distinction between micronized progesterone and synthetic progestins has implications for breast tissue. Data from the Collaborative Group on Hormonal Factors in Breast Cancer meta-analysis (2019), which pooled evidence from 58 studies involving 108,647 postmenopausal women, found that the breast cancer risk increase was lower with micronized progesterone than with other progestins, though the authors noted limited statistical power for micronized progesterone specifically [14]. The KEEPS trial, a randomized controlled trial of early postmenopausal hormone therapy (N=727), used oral micronized progesterone 200 mg for 12 days per cycle and found no significant increase in breast density or cardiovascular risk markers over 4 years [15].

These data points explain why New York clinicians and insurers alike have moved toward formulary inclusion of micronized progesterone as first-line progesterone therapy for endometrial protection.

Prometrium for Specific New York Populations

Medicare beneficiaries in New York face a coverage gap (the "donut hole") that can raise out-of-pocket costs for progesterone mid-year. Generic micronized progesterone's low cost means most Medicare Part D enrollees stay below the initial coverage limit. The Centers for Medicare & Medicaid Services sets the 2026 initial coverage limit at $5,030 in total drug costs [16].

Women using IVF in New York: New York's 2019 fertility insurance mandate requires large group insurers to cover three cycles of IVF, and progesterone supplementation during IVF is a covered component of the treatment cycle. The American Society for Reproductive Medicine practice committee opinion recommends progesterone supplementation during the luteal phase for all IVF cycles [17]. Vaginal micronized progesterone (Endometrin, Crinone) is more commonly used in IVF than oral Prometrium, but oral formulations may be prescribed for patients who cannot tolerate vaginal administration.

Transgender patients in New York: The New York State Department of Financial Services requires insurers to cover medically necessary gender-affirming hormone therapy. Some transgender women use micronized progesterone as an adjunct to estradiol, though the Endocrine Society 2017 guideline on gender-dysphoria treatment notes limited evidence for progesterone's role in feminizing regimens and does not make a strong recommendation for or against its use [18].

Comparing Prometrium to Other Progesterone Options Available in New York

| Product | Type | Route | Approximate NY Monthly Cost (Cash) | FDA-Approved | |---|---|---|---|---| | Prometrium (brand) | Micronized progesterone | Oral | $180 | Yes | | Generic micronized progesterone | Micronized progesterone | Oral | $45 | Yes | | Compounded micronized progesterone (503A) | Micronized progesterone | Oral or vaginal | $25 | No (compounded) | | Medroxyprogesterone acetate (Provera generic) | Synthetic progestin | Oral | $15 | Yes | | Endometrin (vaginal insert) | Micronized progesterone | Vaginal | $350+ | Yes (IVF luteal support) | | Crinone 8% gel | Micronized progesterone | Vaginal | $250+ | Yes (progesterone supplementation) | | Mirena IUD | Levonorgestrel | Intrauterine | $0 co-pay to $1,300 (device cost) | Yes (local endometrial effect) |

The ACOG Practice Bulletin 141 on the management of menopausal symptoms notes that the levonorgestrel intrauterine system provides adequate endometrial protection and may be an option for women who need both contraception and endometrial protection while on estrogen therapy, though this represents off-label use [19].